NCRI 2017 | Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front

David Marks

Nelarabine has shown to be effective in treating relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) in children and adults; however, there are known concerns about its upfront use for T-ALL. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, explains the importance of investigating the outcome of nelarabine treatment in T-ALL patients and the issues surrounding funding of the drug, as well as the lack of patients for clinical trials.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter